Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PBYI
CUSIPN/A
Phone424-248-6500
Debt
Debt-to-Equity Ratio3.14
Current Ratio2.68
Quick Ratio2.64
Price-To-Earnings
Trailing P/E Ratio-5.71
Forward P/E Ratio-12.19
P/E GrowthN/A
Sales & Book Value
Annual Sales$26.20 million
Price / Sales65.10
Cash FlowN/A
Price / CashN/A
Book Value$1.42 per share
Price / Book31.58
Profitability
EPS (Most Recent Fiscal Year)($7.85)
Net Income$-291,950,000.00
Net Margins-146.27%
Return on Equity-367.92%
Return on Assets-112.75%
Miscellaneous
Employees318
Outstanding Shares38,030,000
Market Cap$1.70 billion
Puma Biotechnology (NASDAQ:PBYI) Frequently Asked Questions
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology Inc (NASDAQ:PBYI) announced its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the Zacks' consensus estimate of ($1.26) by $0.09. The biopharmaceutical company earned $50.80 million during the quarter, compared to the consensus estimate of $45.67 million. Puma Biotechnology had a negative net margin of 146.27% and a negative return on equity of 367.92%. During the same period in the previous year, the company posted ($1.38) earnings per share. View Puma Biotechnology's Earnings History.
When is Puma Biotechnology's next earnings date?
What price target have analysts set for PBYI?
9 Wall Street analysts have issued 12-month price targets for Puma Biotechnology's shares. Their predictions range from $77.00 to $164.00. On average, they expect Puma Biotechnology's share price to reach $104.6667 in the next twelve months. This suggests a possible upside of 133.4% from the stock's current price. View Analyst Price Targets for Puma Biotechnology.
What is the consensus analysts' recommendation for Puma Biotechnology?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Puma Biotechnology.
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), FibroGen (FGEN), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL) and Endo International (ENDP).
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the folowing people:
- Mr. Alan H. Auerbach, Founder, Chairman, CEO, Pres & Sec. (Age 48)
- Mr. Charles R. Eyler, Sr. VP of Fin. & Admin. and Treasurer (Age 70)
- Dr. Richard P. Bryce MBChB, MRCGP, MFPM, Chief Medical & Scientific Officer (Age 61)
- Mr. Steven Lo, Chief Commercial Officer (Age 51)
- Mr. Douglas Hunt, Sr. VP of Regulatory Affairs, Medical Writing & Project Management
Has Puma Biotechnology been receiving favorable news coverage?
Media stories about PBYI stock have trended somewhat negative recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Puma Biotechnology earned a news impact score of -0.11 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.52 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Puma Biotechnology.
Who are Puma Biotechnology's major shareholders?
Puma Biotechnology's stock is owned by many different of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (8.73%), BlackRock Inc. (6.63%), FMR LLC (4.55%), Jennison Associates LLC (2.52%), Point72 Asset Management L.P. (2.42%) and Macquarie Group Ltd. (1.24%). Company insiders that own Puma Biotechnology stock include Adage Capital Partners Gp, LL, Alan H Auerbach, Charles R Eyler, Richard Paul Bryce and Robert Charnas. View Institutional Ownership Trends for Puma Biotechnology.
Which institutional investors are selling Puma Biotechnology stock?
PBYI stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Point72 Asset Management L.P., Voya Investment Management LLC, BNP Paribas Arbitrage SA, Eagle Asset Management Inc., Federated Investors Inc. PA, Capital Fund Management S.A. and SG Americas Securities LLC. Company insiders that have sold Puma Biotechnology company stock in the last year include Alan H Auerbach, Charles R Eyler and Richard Paul Bryce. View Insider Buying and Selling for Puma Biotechnology.
Which institutional investors are buying Puma Biotechnology stock?
PBYI stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Jennison Associates LLC, Redwood Investments LLC, BlackRock Inc., FMR LLC, Fred Alger Management Inc., Spark Investment Management LLC and C WorldWide Group Holding A S. View Insider Buying and Selling for Puma Biotechnology.
How do I buy shares of Puma Biotechnology?
Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Puma Biotechnology's stock price today?
One share of PBYI stock can currently be purchased for approximately $44.85.
How big of a company is Puma Biotechnology?
Puma Biotechnology has a market capitalization of $1.70 billion and generates $26.20 million in revenue each year. The biopharmaceutical company earns $-291,950,000.00 in net income (profit) each year or ($7.85) on an earnings per share basis. Puma Biotechnology employs 318 workers across the globe.
How can I contact Puma Biotechnology?
Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The biopharmaceutical company can be reached via phone at 424-248-6500 or via email at [email protected]
MarketBeat Community Rating for Puma Biotechnology (NASDAQ PBYI)
MarketBeat's community ratings are surveys of what our community members think about Puma Biotechnology and other stocks. Vote "Outperform" if you believe PBYI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PBYI will underperform the S&P 500 over the long term. You may vote once every thirty days.
